good health stuff blog
Lack of vitamin D tied to Parkinson’s disease
on 14. Oct 2008 in Parkinson's disease, Vitamin D, Parkinson Disease, Parkinson Disease.

A majority of Parkinson’s disease patients had insufficient levels of vitamin D in a new study from Emory University School of Medicine.

The fraction of Parkinson’s patients with vitamin D insufficiency, 55 percent, was significantly more than patients with Alzheimer’s disease (41 percent) or healthy elderly people (36 percent).

The results are published in the October issue of Archives of Neurology.

The finding adds to evidence that low vitamin D is associated with Parkinson’s, says first author Marian Evatt, MD, assistant professor of neurology at Emory.

Evatt is assistant director of the Movement Disorders Program at Wesley Woods Hospital. The senior author is endocrinologist Vin Tangpricha, MD, assistant professor of medicine at Emory and director of the Endocrine Clinical Research Unit.

Evatt says her team compared Parkinson’s patients to Alzheimer’s patients because they wanted to evaluate the possibility that neurodegenerative diseases in general lead to vitamin D insufficiency.

Most Americans get the majority of their vitamin D from exposure to sunlight or by dietary supplements fortified foods such as milk and packaged cereals are a minor source. Only a few foods in nature contain substantial amounts of vitamin D, such as salmon and tuna.

The body′s ability to produce vitamin D using UV-B radiation from the sun decreases with age, making older individuals at increased risk of vitamin D deficiency.

“We found that vitamin D insufficiency may have a unique association with Parkinson’s, which is intriguing and warrants further investigation,” Evatt says.

The connection could come partly because patients with Parkinson’s have mobility problems and are seldom exposed to the sun, or because low vitamin D levels are in some way related to the genesis or progression of the disease.

She says her team saw their results as striking because their study group came from the Southeast, not a region with long gloomy winters, where vitamin D insufficiency is thought to be more of a problem.

In addition, the study found that the fraction of patients with the lowest levels of vitamin D, described as vitamin D deficiency, was higher (23 percent) in the Parkinson’s group than the Alzheimer’s group (16 percent) or the healthy group (10 percent).

The retrospective study examined 100 people in each group, who were recruited between 1992 and 2007. Every fifth Parkinson’s patient from Emory′s clinical neurology database was selected, then healthy controls and patients with Alzheimer’s disease were matched on age and state of residence.

Vitamin D insufficiency is frequently defined as less than 30 nanograms per milliliter of blood of the 25-hydroxy form (the major storage form) of the vitamin and deficiency as less than 20 nanograms per milliliter. However, most experts agree insufficiency warrants treatment and should not be ignored.

Doctors have known for decades that vitamin D plays a role in bone formation, Evatt says. More recently, scientists have been uncovering its effects elsewhere, including producing peptides that fight microbes in the skin, regulating blood pressure and insulin levels, and maintaining the nervous system. Low vitamin D levels also appear to increase the risk of several cancers and auto-immune diseases such as multiple sclerosis and diabetes.

Parkinson’s disease affects nerve cells in several parts of the brain, particularly those that use the chemical messenger dopamine to control movement. The most common symptoms are tremor, stiffness and slowness of movement. These can be treated with oral replacement of dopamine.

Previous studies have shown that the part of the brain affected most by Parkinson’s, the substantia nigra, has high levels of the vitamin D receptor, which suggests vitamin D may be important for normal functions of these cells, Evatt says.

Emory clinicians are conducting further research to investigate whether vitamin D insufficiency is a cause or possibly a result of having Parkinson’s. In a pilot study, Parkinson’s patients are receiving either standard or larger doses of vitamin D, with an eye towards possibly reducing the severity of their condition.

Lessons from yeast: A possible cure for Parkinson’s disease?
on 15. Aug 2008 in Parkinson Disease, Parkinson Disease.

Parkinson disease (PD) is a debilitating and lethal neurodegenerative disease, for which there is currently no cure. It is caused by the progressive loss of nerve cells that produce the chemical dopamine and is characterized by the accumulation of abnormal aggregates of a protein called alpha-syn in these dopaminergic nerve cells. Several previous studies have suggested that the alpha-syn aggregates contribute to PD pathology, so it is possible that an agent that inhibits and/or, better yet, reverses alpha-syn aggregation could be eventually used as a therapy for PD. Evidence to suggest that agents that disrupt alpha-syn aggregation might have beneficial effects in individuals with PD has now been provided by a team of researchers, at the Ecole Polytechnique Fédérale de Lausanne, Switzerland, and the University of Pennsylvania School of Medicine, Philadelphia, who studied a rat model of the disease.

In the study, it was found that a protein that yeast uses to protect itself from protein aggregation (there is no similar protein in mammals), called Hsp104, dramatically reduced both the formation of alpha-syn aggregates and the degeneration of neurons in the brain in a rat mdoel of PD. In vitro studies showed that Hsp104 not only inhibited alpha-syn aggregate formation, but also interacted with mammalian proteins to disassemble them. The authors therefore suggest that Hsp104 should be considered as a potential strategy for the treatment of individuals with PD, after further studies on the safety of introducing Hsp104 into the brain.

Source

Adult stem cell findings offer new hope for Parkinson’s cure
on 06. Jun 2008 in Parkinson Disease, Parkinson Disease, Stem Cells, Stem Cells.

Research released today provides evidence that a cure for Parkinson’s disease could lie just inside the nose of patients themselves.

The Griffith University study published today (Thursday 9am US East Coast) in the journal Stem Cells found that adult stem cells harvested from the noses of Parkins…

,
Neural cell transplants may help those with Parkinson’s disease
on 19. May 2008 in Parkinson Disease, Parkinson Disease.

The current issue of CELL TRANSPLANTATION (Vol. 17:4) features a number of publications by researchers seeking new ways to treat Parkinson’s disease (PD), a neurological disease characterized by muscle rigidity, tremor and slowed physical movements related to insufficient levels of dopamine (DA) i…

First diagnostic test for Alzheimer’s and Parkinson’s disease on the horizon
on 08. Apr 2008 in Parkinson Disease, Parkinson Disease, Alzheimers Dementia, Alzheimers - Dementia.

A new blood test that can give an early diagnosis of neurodegenerative disease and distinguish between Parkinson’s and Alzheimer’s disease could be launched this summer, reports Marina Murphy in SCI’s Chemistry & Industry magazine.

Manufacturer, Oklahoma-based proteomics company, Power3 Med…

,
Pieces coming together in Parkinson’s, cholesterol puzzle
on 05. Apr 2008 in Parkinson Disease, Parkinson Disease.

In 2006, University of North Carolina at Chapel Hill researchers published a study that found people with low levels of LDL cholesterol are more likely to have Parkinson’s disease than people with high LDL levels.

But that study could not answer the question of whether low LDL (low-density lipopr…

New research provides genetic clue to Parkinson’s disease
on 24. Mar 2008 in Parkinson Disease, Parkinson Disease.

Gene linked to development of the disease in those with a family history

Researchers at Rhode Island Hospital and The Warren Alpert Medical School of Brown University have discovered a gene that could hold the key to developing new treatments for Parkinson’s disease – a progressive and often …

Therapeutic cloning treats Parkinson’s disease in mice
on 24. Mar 2008 in Parkinson Disease, Parkinson Disease.

Research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson’s disease in mice. The study’s results are published in the March 23 online edition of the journa…

Stem cell research aims to tackle Parkinson’s disease
on 18. Jan 2008 in Parkinson Disease, Parkinson Disease.

New ways to grow brain cells in the laboratory could eventually provide a way to treat Parkinson’s disease
Scientists in Sweden are developing new ways to grow brain cells in the laboratory that could one day be used to treat patients with Parkinson’s disease, an international conference of biolo…

Sleep chemical central to effectiveness of deep brain stimulation
on 24. Dec 2007 in Parkinson Disease, Parkinson Disease, brain news & ailments, Brain News & Ailments.

A brain chemical that makes us sleepy also appears to play a central role in the success of deep brain stimulation to ease symptoms in patients with Parkinson’s disease and other brain disorders. The surprising finding is outlined in a paper published online Dec. 23 in Nature Medicine.

The work…

,